NEW YORK – BGI Genomics announced on Wednesday that its colorectal cancer screening test has received CE marking.
The DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes can detect abnormal methylation of the genes in stool DNA from human fecal samples. The genes are highly specific markers for colorectal cancer cells, the company said in a statement.
The noninvasive test is intended to help diagnose patients who are recommended by clinicians to receive a diagnostic colonoscopy.
Shenzhen, China-based BGI Genomics is the clinical genetic testing and research services arm of China's BGI Group.